PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCisatracurium besylate
Cisatracurium besylate
Cisatracurium Besylate (cisatracurium besylate) is a small molecule pharmaceutical. Cisatracurium besylate was first approved as Nimbex on 1995-12-15.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cisatracurium besylate (discontinued: Cisatracurium besylate, Nimbex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisatracurium besylate
Tradename
Company
Number
Date
Products
NIMBEXAbbVieN-020551 DISCN1995-12-15
1 products, RLD
NIMBEX PRESERVATIVE FREEAbbVieN-020551 DISCN1995-12-15
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cisatracuriumANDA2025-02-21
cisatracurium besylateANDA2026-06-30
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
158 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromuscular blockadeD019148———2—8919
AnesthesiaD000758—————6814
General anesthesiaD000768————13812
Respiratory distress syndromeD012128EFO_1000637J801223412
Acute lung injuryD055371EFO_0004610—1223412
Newborn respiratory distress syndromeD012127—P221123310
Postoperative painD010149—G89.18———448
Emergence deliriumD000071257——1——247
Delayed emergence from anesthesiaD055191—————527
DeliriumD003693—R41.01——146
Show 64 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FasciculationD005207—R25.3——2—13
HemorrhageD006470MP_0001914R58——1—12
MeningiomaD008579EFO_0003098D32.9——1——1
MyalgiaD063806—M79.1——1——1
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoxiaD000860—R09.021———12
Femur head necrosisD005271——1————1
NecrosisD009336——1————1
Respiratory tract diseasesD012140——1————1
Respiration disordersD012120—J00-J991————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intravenous anesthesiaD000771——————66
Epidural anesthesiaD000767——————22
Aortic dissectionD000784—I71.0————22
Conduction anesthesiaD000765——————22
Thoracic surgical proceduresD019616——————22
Hip fracturesD006620EFO_0003964S72.00————22
Breast neoplasmsD001943EFO_0003869C50————22
DiseaseD004194EFO_0000408R69————22
Neuromuscular monitoringD061886——————22
DepressionD003863—F33.9————22
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCisatracurium besylate
INNcisatracurium besilate
Description
Cisatracurium besylate is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia. It has a role as a muscle relaxant and a nicotinic antagonist. It is a quaternary ammonium salt, an atracurium besylate and an organosulfonate salt. It contains a cisatracurium.
Classification
Small molecule
Drug classquaternary ammonium derivatives: neuromuscular blocking agents
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1
Identifiers
PDB—
CAS-ID96946-42-8
RxCUI—
ChEMBL IDCHEMBL1200641
ChEBI ID3721
PubChem CID62886
DrugBankDB00565
UNII ID80YS8O1MBS (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 731 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,478 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use